|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Incorporating adjuvant trastuzumab data into the Adjuvant! Online computer model |
|
|
| Track 3 |
Impact of adjuvant trastuzumab on relapse and survival |
|
|
| Track 4 |
Clinical implications of the adjuvant trastuzumab data |
|
|
| Track 5 |
NSABP-B-31 and NCCTG-N9831: Effect of trastuzumab on cardiac function |
|
|
| Track 6 |
Concurrent versus sequential adjuvant trastuzumab with chemotherapy |
|
|
| Track 7 |
Duration and timing of adjuvant trastuzumab therapy |
|
|
| Track 8 |
Monitoring cardiac function in patients receiving adjuvant trastuzumab |
|
|
| Track 9 |
Impact of targeted therapy on breast cancer mortality |
|
|
| Track 10 |
Canadian study validating the Adjuvant! Online computer model |
|
|
| Track 11 |
Overview of the adjuvant trials of aromatase inhibitors |
|
|
| Track 12 |
Five years of adjuvant tamoxifen versus switching to an aromatase inhibitor |
|
|
| Track 13 |
Duration of aromatase inhibitor therapy following adjuvant tamoxifen |
|
|
| Track 14 |
Adjuvant hormonal therapy for premenopausal patients with ER-positive,
HER2-positive disease |
|
|
| Track 15 |
Efficacy of chemotherapy in patients with ER-positive versus ER-negative disease |
|
|
| Track 16 |
TAC versus FEC in patients with ER-positive breast cancer |
|
|
| Track 17 |
EBCTCG meta-analysis of chemotherapy and hormonal therapy in early breast cancer |
|
|
| Track 18 |
Impact of adjuvant therapy on micrometastatic disease |
|
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy for
metastatic breast cancer |
|
|
| Track 3 |
Clinical use of bevacizumab based on the E2100 data |
|
|
| Track 4 |
Nanoparticle albumin-bound (nab) paclitaxel as single-agent and combination therapy |
|
|
| Track 5 |
Continuation of bevacizumab after disease progression |
|
|
| Track 6 |
Clinical benefits and efficacy of nab paclitaxel |
|
|
| Track 7 |
Side-effect profile of nab paclitaxel |
|
|
| Track 8 |
Estimated efficacy of nab paclitaxel compared to standard paclitaxel |
|
|
| Track 9 |
Strategies to prevent taxane-associated neuropathy |
|
|
| Track 10 |
Advantage of avoiding premedication with nab paclitaxel |
|
|
| Track 11 |
Role of nab paclitaxel in the metastatic and adjuvant settings |
|
|
| Track 12 |
Management of ER/PR-negative, HER2-negative metastatic disease |
|
|
| Track 13 |
Selection of first-line chemotherapy for the treatment of metastatic disease |
|
|
| Track 14 |
Combination versus single-agent therapy in the treatment of metastatic breast cancer |
|
|
| Track 15 |
Efficacy of capecitabine versus taxane therapy in the metastatic setting |
|
|
| |
|
|
|
 |
G Thomas Budd, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of
Case Western Reserve University
Cleveland Clinic Foundation
Cleveland, Ohio
Conducted on April 18, 2005
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Clinical indications for capecitabine in the treatment of metastatic breast cancer |
|
|
| Track 3 |
Dose and schedule of nab paclitaxel in clinical practice |
|
|
| Track 4 |
Selection of a taxane in the metastatic setting: nab paclitaxel, docetaxel or paclitaxel |
|
|
| Track 5 |
Rationale for combining bevacizumab with taxane therapy |
|
|
| Track 6 |
SWOG-S0221: Dose-dense versus metronomic AC with paclitaxel |
|
|
| Track 7 |
Up-front use of aromatase inhibitors for adjuvant therapy |
|
|
| Track 8 |
Switching from adjuvant tamoxifen to an aromatase inhibitor |
|
|
| Track 9 |
Selection of an aromatase inhibitor after adjuvant tamoxifen |
|
|
| Track 10 |
Trastuzumab with or without chemotherapy in patients with metastatic disease |
|
|
| Track 11 |
Fulvestrant for postmenopausal patients with ER/PR-positive metastatic breast cancer |
|
|
| Track 12 |
Potential benefit of fulvestrant in the adjuvant setting |
|
|
| Track 13 |
Prognostic and clinical value of circulating tumor cell assay |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Single-agent versus combination chemotherapy in metastatic disease |
|
|
| Track 3 |
Dose modification with capecitabine and impact on efficacy |
|
|
| Track 4 |
Front-line fulvestrant following adjuvant aromatase inhibitor therapy |
|
|
| Track 5 |
Selection of hormone therapy for metastatic disease following adjuvant tamoxifen |
|
|
| Track 6 |
Dose and schedule of fulvestrant in clinical practice |
|
|
| Track 7 |
Strategy of combining fulvestrant with an aromatase inhibitor |
|
|
| Track 8 |
Hormonal therapy for premenopausal patients with metastatic disease |
|
|
|
|
